臨床婦人科産科71巻1号

2017年01月発行

合併増大号　今月の臨床 性ステロイドホルモン研究の最前線と臨床応用 性ステロイドホルモンの副作用の疫学

子宮内膜癌・乳がん

著者： 髙松潔¹ 杉山重里¹ 小川真里子¹

所属機関： ¹東京歯科大学市川総合病院産婦人科

ページ範囲：P.148 - P.158

●性ステロイドホルモン投与は子宮内膜癌や乳がんリスクに影響を与えるが，そのインパクトは小さく，適切なレジメンを選択することによってリスクを低下させることができる．

●子宮内膜癌については，OC・LEP服用によりリスクは低下する．HRTでは，エストロゲン単独投与にてリスクは上昇するが，黄体ホルモンを適切な量，かつ，適切な期間で併用すれば，リスクは低下する．

●乳がんについては，OC・LEP服用によりリスクは上昇する可能性があるが，絶対リスクは小さい．HRTが乳がんリスクに及ぼす影響は小さく，主として併用される黄体ホルモンとHRT施行期間に関連している．

参考文献

1）Deligdisch L : Hormonal pathology of the endometirum. Mod Pathol 13 : 285─294, 2000

2）Whitehead MI, et al : Controversies concerning the safety of estrogen replacement therapy. Am J Obstet Gynecol 156 : 1313─1322, 1987

3）Weiderpass E, et al : Low-potency oestrogen and risk of endometrial cancer : a case-controll study. Lancet 353 : 1824─1828, 1999

4）Sturdee DW : Are progestins really necessary as part of a combined HRT regimen? Climacteric 16（Suppl 1）: 79─84, 2013

5）日本臨床腫瘍学会 : 子宮がん．新臨床腫瘍学（改訂第4版）．pp453─466，南江堂，2015

6）Gierisch JM, et al : Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers : a systematic review. Cancer Epidemiol Biomarkers Prev 22 : 1931─1943, 2013

7）Collaborative Group on Epidemiological Studies on Endometrial Cancer : Endometrial cancer and oral contraceptives : an individual participant meta-analysis of 27276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol 16 : 1061─1070, 2015

8）国立がん研究センターがん情報サービス「がん登録・統計」　http://ganjoho.jp/reg_stat/statistics/stat/summary.html（2016年5月31日アクセス）

9）Grady D, et al : Hormone replacement therapy and endometrial cancer risk : a meta-analysis. Obstet Gynecol 85 : 304─313, 1995

10）Chlebowski RT, et al : Continuous Combined Estrogen Plus Progestin and Endometrial Cancer : The Women's Health Initiative Randomized Trial. J Natl Cancer Inst 108 : djv350, 2016

11）水沼英樹 : HRTと子宮内膜がんリスク : 本邦における調査研究から．日更医誌10 : 77─80, 2002

12）高松　潔，他 : 子宮体がんとホルモン補充療法．産婦の実際62 : 1173─1179, 2013

13）Woodruff JD, et al : Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens（Premarin）with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 170（5 Pt 1）: 1213─1223, 1994

14）Bjarnason K, et al : Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas 32 : 161─170, 1999

15）Jaakkola S, et al : Endometrial cancer associated with various forms of postmenopausal hormone therapy : a case control study. Int J Cancer 128 : 1644─1651, 2011

16）Orbo A, et al : Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia : a national multicentre randomised trial. BJOG 121 : 477─486, 2014

17）Yager JD : Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 27 : 67─73, 2000

18）Yager JD, et al : Estrogen carcinogenesis in breast cancer. N Engl J Med 354 : 270─282, 2006

19）谷口英樹，他 : 組織幹細胞の機能異常と癌．実験医学24（増） : 56─61, 2006

20）Al-Hajj M, et al : Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100 : 3983─3988, 2003

21）Beaber EF, et al : Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age. Cancer Res 74 : 4078─4089, 2014

22）Suzuki R, et al : Japan Public Health Center-Based Prospective Study Group : Alcohol consumption-associated breast cancer incidence and potential effect modifiers : the Japan Public Health Center-based prospective study. Int J Cancer 127 : 685─695, 2010

23）Writing Group for the Women's Health Initiative Investigators : Risks and benefits of estrogen plus progestin in healthy postmenopausal women : Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 288 : 321─333, 2002

24）Beral V, et al : Million Women Study Collaborators : Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103 : 296─305, 2011

25）Beral V : Million Women Study Collaborators : Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 : 419─427, 2003

26）The Women's Health Initiative Steering Committee : Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291 : 1701─1712, 2004

27）Anderson GL, et al : Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy : extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 13 : 476─486, 2012

28）Chlebowski RT, et al : Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative. J Natl Compr Canc Netw 13 : 917─924, 2015

29）Chen WY, et al : Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 166 : 1027─1032, 2006

30）日本産科婦人科学会・日本女性医学学会 : ホルモン補充療法ガイドライン2012年度版．日本産科婦人科学会，2012

31）de Villiers TJ, et al : Revised global consensus statement on menopausal hormone therapy. Climacteric 19 : 313─315, 2016

32）高松　潔，他 : HRTと乳癌．産と婦80（Suppl.） : 345─353, 2013

33）Opatrny L, et al : Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 115 : 169─175, 2008

34）Corrao G, et al : Menopause hormone replacement therapy and cancer risk : an Italian record linkage investigation. Ann Oncol 19 : 150─155, 2008

35）Fournier A, et al : Unequal risks for breast cancer associated with different hormone replacement therapies : results from the E3N cohort study. Breast Cancer Res Treat 107 : 103─111, 2008

36）Mueck AO, et al : Use of dydrogesterone in hormone replacement therapy. Maturitas 65（Suppl 1）: S51─S60, 2009

37）Lyytinen HK, et al : A case-control study on hormone therapy as a risk factor for breast cancer in Finland : intrauterine system carries a risk as well. Int J Cancer 126 : 483─489, 2010